AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02662673 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Focal High Intensity Focused Ultrasound (HIFU) treatment
Description: Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
Study NCT01648465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
Study NCT01740167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health promotion lifestyle program
Description: Individual counseling, once a month, total 3 times.
Study NCT02164253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: 30 mg/kg per day, oral use
Study NCT03710187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 50 mg IV Q6h
Study NCT03710187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 50 mg IV Q6h
Study NCT00231816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (concomitant)
Description: a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
Study NCT00231816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Influenza Vaccine
Description: a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
Study NCT00231816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Nonconcomitant)
Description: Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
Study NCT02079896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexaptepid pegol (NOX-H94)
Description: anti-hepcidin L-RNA-aptamer (Spiegelmer)
Study NCT02079896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02079896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02991183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: A psychological therapy to help people i) notice and accept difficult thoughts and emotions; ii) identify what they value in life and iii) make changes to their behaviour to promote these values.
Study NCT03715556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Administration of the drug will be blinded within the first 48 hours for the principal investigator. Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated.
Study NCT03715556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% physiological solution
Description: Administration of 0.9% physiological solution.
Study NCT03715556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% physiological solution
Description: Administration of 0.9% physiological solution.
Study NCT02192580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
Study NCT00412334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1200-1600mg/day po
Study NCT00412334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000-1200mg/day po
Study NCT00412334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 360 micrograms sc weekly
Study NCT00412334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc twice weekly
Study NCT03696836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trammpolin® meniscus prosthesis
Description: Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
Study NCT03800381 — intervention group
Intervention type: OTHER
Intervention: Observational PK study
Description: The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
Study NCT04089748 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy with cisplatine
Description: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
Study NCT02521285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO
Study NCT02521285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02521285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02521285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02521285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02521285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00689039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: ER tablet, administered as single and repeated doses.
Study NCT00689039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, administered as single and repeated doses.
Study NCT00548665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid ultrasound for plaque screening
Description: Carotid ultrasound for plaque screening
Study NCT00548665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice for smoking cessation
Description: We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
Study NCT00548665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice for smoking cessation
Description: We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
Study NCT01784224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves
Study NCT01511406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
Study NCT02246530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection into PTRCT
Description: Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.~PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug.
Study NCT02246530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subacromial steroid bursal injection
Description: Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
Study NCT02254603 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acupuncture
Description: Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
Study NCT02254603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
Study NCT02254603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga exercise
Description: Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
Study NCT01303341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01303341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01303341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Given PO
Study NCT01303341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT04644952 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT01539824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium obuense
Description: IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
Study NCT01539824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
Study NCT03750045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Jamar
Description: The grip strength was evaluated through a dynamometer JAMAR 5030-J, formed by two parallel steel bars, one stationary and a mobile one, which can be adjusted in five different positions. The volunteer was sitting with a neutrally rotated abducted shoulder, elbow flexed at 90°, the forearm in neutral position, and the wrist between 0° and 30° of extension, 0° to 15° of ulnar variance and it was requested that he or she made the grip movement. This test was performed three times with a one-minute-break between each one.
Study NCT03750045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wooden box
Description: The motor coordination evaluation was made through the measurement of the time spent to perform the task of fitting. To do so, a wooden box was built. In its upper part, there is a circular orifice with 6 cm of diameter.
Study NCT03750045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual environment
Description: The system proposed is composed by a virtual environment and an access device. The Leap Motion was used as the access device, making it possible to capture the movements performed by the hands.
Study NCT00593294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: 45 minutes each day for three times/week for 6 months
Study NCT00593294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC - Drospirenone plus Ethynylestradiol
Description: 1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
Study NCT00593294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin, polyvitamins tablets
Description: Tablet of vitamin 1cp for 21 days each month for 6 months
Study NCT02409069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)
Study NCT02409069 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation (Nemos®, Cerbomed GmbH)
Study NCT01495832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse Group
Description: The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
Study NCT04270266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Attend educational sessions
Study NCT01495832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will consume comparator foods for 12 weeks.
Study NCT02932566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
Study NCT02932566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
Study NCT04601701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Ophthalmic and Intravitreal Dexamethasone.
Description: Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
Study NCT04270266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Attend meditation sessions
Study NCT04270266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04270266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06207188 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT01334021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT01334021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT01334021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing
Study NCT02402816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing ON
Description: MultiPoint Pacing ON
Study NCT02402816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Description: Implantable cardioverter-defibrillator (ICD)
Study NCT01780311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)
Study NCT01780311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Study NCT04771494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power and execution speed as a function of instability experience
Description: Each subject performed 3 repetitions for the light load (40% RM; VMP > 1.0 m/s), with 1 minute rest; 2 repetitions for the medium load (60% RM; 0.65 m/s ≤ VMP ≤ 1.0 m/s) with 2 minutes rest and 1 repetition for the heavy load (80% RM; VMP \< 0.65 m/s) with 4 minutes rest. A metronome was used for the start countdown and to time the eccentric and concentric portions of the exercise.~Subjects began the bench press with their elbows fully extended, maintaining a grip distance slightly greater than shoulder width. The bar was then lowered to their chest and then applying as much thrust as possible until full elbow extension on a 2-1-0 count. The timing sequence involved 2 seconds for the eccentric phase, a 1 second hold (to minimise the contribution of the rebound effect and allow for more reproducible and consistent measurements) and for the concentric up phase the highest possible execution speed, until the bar returned to the starting position.
Study NCT04601701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Ophthalmic.
Description: Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
Study NCT03633370 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multifaceted intervention including 3 components
Description: Multifaceted intervention including Dispatcher training to improve cardiac phone recognition, mobile application to send bystanders on cardiac arrest location before first professionals rescuers and motivational support for volunteer bystanders
Study NCT04827069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Study NCT04555486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: Intervention, drug, DCR-PHXC
Study NCT04555486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Placebo comparator
Study NCT03044509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Secreted cytokine assay
Description: Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
Study NCT03044509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intracellular cytokine assay
Description: Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
Study NCT03670680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Lina LibrataTM
Description: Use of the Lina LibrataTM
Study NCT03009058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM-101
Description: A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
Study NCT03009058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of Care chemotherapy
Study NCT03009058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Standard of Care chemotherapy
Study NCT03009058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Standard of Care chemotherapy
Study NCT03009058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Standard of Care chemotherapy
Study NCT03009058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Standard of Care chemotherapy
Study NCT03009058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Standard of Care chemotherapy
Study NCT03009058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Standard of Care chemotherapy
Study NCT03009058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Standard of Care immunotherapy
Study NCT03009058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD1
Description: Standard of Care immunotherapy
Study NCT03009058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Standard of Care immunotherapy
Study NCT03009058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard of Care chemotherapy
Study NCT03596502 — intervention group
Intervention type: DRUG
Intervention: Direct oral anticoagulants (DOACs)
Description: Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
Study NCT03596502 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.